查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1878836

圍產期感染市場－全球產業規模、佔有率、趨勢、機會和預測，按感染類型、治療方法、診斷方法、最終用戶、地區和競爭格局分類，2020-2030年預測

Perinatal Infections Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Infection Type, By Treatment, By Diagnosis, By End user, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球圍產期感染市場規模為16億美元，預計2030年將以5.30%的複合年成長率成長至21.8億美元。該市場專注於針對妊娠或分娩期間由母體傳染給胎兒的病毒或細菌感染的診斷和治療解決方案。市場擴張的主要促進因素包括全球範圍內此類感染盛行率的上升、醫療保健支出的增加以及公眾對母嬰健康意識的提高。診斷方法和治療手段的持續技術進步，有助於更早發現感染並採取更有效的干涉措施，從而進一步促進市場成長。

市場概覽
預測期 2026-2030
2024年市場規模 16億美元
2030年市場規模 21.8億美元
2025-2030年複合年成長率 5.3%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球圍產期感染市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依感染類型分類（鉅細胞病毒感染、腸病毒感染、生殖器皰疹、淋病、人類免疫缺乏病毒、李斯特菌病、淋巴球性脈絡叢腦膜炎病毒、德國麻疹、梅毒、水痘、其他）
    • 依治療方法分類（抗生素、抗病毒藥物、抗病毒藥物、其他）
    • 按診斷（母體檢測、新生兒檢測、其他）
    • 按最終使用者（醫院和診所、門診中心、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美圍產期感染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲圍產期感染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區圍產期感染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲圍產期感染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲圍產期感染市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球圍產期感染市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Merck KGaA
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories, Inc
  • Hologic Inc.
  • Gilead Sciences, Inc.
  • Emcure Pharmaceuticals Limited.
  • Cipla Inc.
  • Bausch Health Companies Inc
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 20969

The Global Perinatal Infections Market, valued at USD 1.6 Billion in 2024, is projected to experience a CAGR of 5.30% to reach USD 2.18 Billion by 2030. The Global Perinatal Infections Market focuses on diagnostic and therapeutic solutions for infections caused by viruses or bacteria transmitted from a mother to her fetus during gestation or childbirth. Market expansion is substantially driven by the increasing global prevalence of these infections, alongside rising healthcare expenditure and heightened public awareness concerning maternal and child health. Further growth is supported by continuous technological advancements in diagnostic methodologies and treatment modalities, facilitating earlier detection and more effective interventions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.6 Billion
Market Size 2030USD 2.18 Billion
CAGR 2025-20305.3%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Key Market Drivers

The Global Perinatal Infections Market is significantly shaped by sustained technological advancements in diagnostics and treatment. Innovations in diagnostic platforms are continuously enhancing the precision and accessibility of early detection for perinatal infections. This includes the development of non-invasive prenatal tests, which allow for screening of complex fetal genetic conditions with reduced risk. For instance, according to Natera, in August 2025, their Fetal Focus test, a noninvasive prenatal test for inherited conditions, was launched, supported by data from a clinical trial that initiated in 2023 and had enrolled approximately 1,300 participants. These diagnostic breakthroughs enable earlier and more accurate identification of infections, facilitating timely intervention and improving outcomes for both mother and child.

Key Market Challenges

The scarcity of adequately skilled healthcare professionals capable of providing accurate diagnosis and comprehensive treatment for complex perinatal conditions significantly impedes the growth of the Global Perinatal Infections Market. This shortage directly limits the effective deployment and utilization of innovative diagnostic technologies and therapeutic solutions. When there are insufficient trained personnel, particularly those specializing in infectious diseases, the ability to promptly and accurately identify perinatal infections is compromised. This often leads to delayed treatment initiation, reduced efficacy of available interventions, and poorer maternal and neonatal outcomes.

Key Market Trends

The growing adoption of personalized medicine approaches represents a pivotal trend reshaping the Global Perinatal Infections Market by moving beyond standardized treatments to highly individualized care. This trend emphasizes tailoring diagnostic and therapeutic interventions based on a mother's unique genetic profile, microbial resistance patterns, and immune response, aiming to optimize outcomes for both mother and child. Such customization drives demand for advanced molecular diagnostics capable of identifying specific pathogens and host genetic predispositions with high precision. According to the Personalized Medicine Coalition, the FDA approved 18 new personalized medicines in 2024, constituting 38% of all newly approved therapeutic molecular entities across various treatment areas. Companies are increasingly collaborating in this space; Roche and Janssen Biotech Inc. joined forces in February 2023 to develop personalized and targeted therapies alongside companion diagnostics, signaling a strategic focus on this tailored medical paradigm.

Key Market Players

  • Merck KGaA
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories, Inc
  • Hologic Inc.
  • Gilead Sciences, Inc.
  • Emcure Pharmaceuticals Limited.
  • Cipla Inc.
  • Bausch Health Companies Inc
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.

Report Scope:

In this report, the Global Perinatal Infections Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Perinatal Infections Market, By Infection Type:

  • Cytomegalovirus Infection
  • Enterovirus Infection
  • Genital Herpes
  • Gonorrhoea
  • Human Immunodeficiency Virus
  • Listeriosis Lymphocytic Choriomeningitis Virus
  • Rubella
  • Syphilis
  • Varicella
  • Others

Perinatal Infections Market, By Treatment:

  • Antibiotics
  • Antiviral
  • Antiretroviral
  • Others

Perinatal Infections Market, By Diagnosis:

  • Maternal Test
  • Neonatal Test
  • Others

Perinatal Infections Market, By End user:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Perinatal Infections Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Perinatal Infections Market.

Available Customizations:

Global Perinatal Infections Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Perinatal Infections Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Infection Type (Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes, Gonorrhoea, Human Immunodeficiency Virus, Listeriosis Lymphocytic Choriomeningitis Virus, Rubella, Syphilis, Varicella, Others)
    • 5.2.2. By Treatment (Antibiotics, Antiviral, Antiretroviral, Others)
    • 5.2.3. By Diagnosis (Maternal Test, Neonatal Test, Others)
    • 5.2.4. By End user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Perinatal Infections Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Infection Type
    • 6.2.2. By Treatment
    • 6.2.3. By Diagnosis
    • 6.2.4. By End user
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Perinatal Infections Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Infection Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Diagnosis
        • 6.3.1.2.4. By End user
    • 6.3.2. Canada Perinatal Infections Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Infection Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Diagnosis
        • 6.3.2.2.4. By End user
    • 6.3.3. Mexico Perinatal Infections Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Infection Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Diagnosis
        • 6.3.3.2.4. By End user

7. Europe Perinatal Infections Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Infection Type
    • 7.2.2. By Treatment
    • 7.2.3. By Diagnosis
    • 7.2.4. By End user
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Perinatal Infections Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Infection Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Diagnosis
        • 7.3.1.2.4. By End user
    • 7.3.2. France Perinatal Infections Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Infection Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Diagnosis
        • 7.3.2.2.4. By End user
    • 7.3.3. United Kingdom Perinatal Infections Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Infection Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Diagnosis
        • 7.3.3.2.4. By End user
    • 7.3.4. Italy Perinatal Infections Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Infection Type
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Diagnosis
        • 7.3.4.2.4. By End user
    • 7.3.5. Spain Perinatal Infections Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Infection Type
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Diagnosis
        • 7.3.5.2.4. By End user

8. Asia Pacific Perinatal Infections Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Infection Type
    • 8.2.2. By Treatment
    • 8.2.3. By Diagnosis
    • 8.2.4. By End user
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Perinatal Infections Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Infection Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Diagnosis
        • 8.3.1.2.4. By End user
    • 8.3.2. India Perinatal Infections Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Infection Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Diagnosis
        • 8.3.2.2.4. By End user
    • 8.3.3. Japan Perinatal Infections Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Infection Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Diagnosis
        • 8.3.3.2.4. By End user
    • 8.3.4. South Korea Perinatal Infections Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Infection Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Diagnosis
        • 8.3.4.2.4. By End user
    • 8.3.5. Australia Perinatal Infections Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Infection Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Diagnosis
        • 8.3.5.2.4. By End user

9. Middle East & Africa Perinatal Infections Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Infection Type
    • 9.2.2. By Treatment
    • 9.2.3. By Diagnosis
    • 9.2.4. By End user
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Perinatal Infections Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Infection Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Diagnosis
        • 9.3.1.2.4. By End user
    • 9.3.2. UAE Perinatal Infections Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Infection Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Diagnosis
        • 9.3.2.2.4. By End user
    • 9.3.3. South Africa Perinatal Infections Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Infection Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Diagnosis
        • 9.3.3.2.4. By End user

10. South America Perinatal Infections Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Infection Type
    • 10.2.2. By Treatment
    • 10.2.3. By Diagnosis
    • 10.2.4. By End user
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Perinatal Infections Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Infection Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Diagnosis
        • 10.3.1.2.4. By End user
    • 10.3.2. Colombia Perinatal Infections Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Infection Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Diagnosis
        • 10.3.2.2.4. By End user
    • 10.3.3. Argentina Perinatal Infections Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Infection Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Diagnosis
        • 10.3.3.2.4. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Perinatal Infections Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Beckman Coulter Inc.
  • 15.3. Bio-Rad Laboratories, Inc
  • 15.4. Hologic Inc.
  • 15.5. Gilead Sciences, Inc.
  • 15.6. Emcure Pharmaceuticals Limited.
  • 15.7. Cipla Inc.
  • 15.8. Bausch Health Companies Inc
  • 15.9. Johnson & Johnson
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer